Adicet Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Adicet Bio, Inc. (formerly resTORbio, Inc.) on September 25, 2020. The filing primarily addresses Item 4.01, reporting a change in the registrant's certifying accountant. The report covers events surrounding the completion of a merger on September 15, 2020, where resTORbio acquired Prior Adicet (formerly Adicet Bio, Inc.), resulting in a name change for the parent company to Adicet Bio, Inc.
Key Financial Metrics
The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the current period. The document focuses on corporate governance and accounting transitions rather than operational financial performance.
Material Changes and Accounting Transition
- Accountant Change: On September 24, 2020, the Audit Committee appointed KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020. PricewaterhouseCoopers LLP (PwC) was dismissed on September 25, 2020.
- Merger Context: The change in auditors is a direct result of the Merger completed on September 15, 2020, between resTORbio and Prior Adicet.
- Prior Audit Status: PwC's reports for Prior Adicet for the years ended December 31, 2019, and 2018 did not contain adverse opinions or disclaimers. However, the 2019 report included an explanatory paragraph regarding substantial doubt about Prior Adicet's ability to continue as a going concern.
Management Commentary, Risks, and Contingencies
The filing discloses specific material weaknesses in Prior Adicet's internal controls over financial reporting identified during the years ended December 31, 2019, and 2018, and the interim period through September 25, 2020. These weaknesses include:
- Lack of a sufficient number of accounting professionals with appropriate experience and training, leading to an ineffective control environment.
- Absence of formal accounting policies, procedures, and controls for complete, accurate, and timely financial reporting.
- Ineffective controls over segregation of duties regarding account reconciliations and manual journal entries.
- Lack of formal processes to analyze, account for, and disclose complex transactions.
There were no disagreements with PwC on accounting principles or practices, nor were there any reportable events other than the material weaknesses listed above. Prior Adicet did not consult KPMG regarding accounting principles or audit opinions prior to the appointment.
Investor Verification Checklist
- Verify the transition timeline and scope of work between the outgoing auditor (PwC) and the incoming auditor (KPMG).
- Review the company's remediation plan for the disclosed material weaknesses in internal controls over financial reporting.
- Assess the impact of the "substantial doubt" regarding going concern status noted in Prior Adicet's 2019 audit on the merged entity's current financial stability.
- Confirm the integration of financial reporting systems following the merger of resTORbio and Prior Adicet.